Linopristin/flopristin
| Combination of | |
|---|---|
| Linopristin | Antibiotic |
| Flopristin | Antibiotic |
| Clinical data | |
| Other names | NXL103; XRP 2868 |
| Identifiers | |
| CAS Number | |
Linopristin/flopristin (development codes NXL103 and XRP 2868) is an experimental drug candidate under development by Novexel. It is an oral streptogramin antibiotic that has potent in vitro activity against certain Gram-positive bacteria including methicillin resistant Staphylococcus aureus (MRSA),[1] as well as the important respiratory pathogens including penicillin-, macrolide- and quinolone-resistant strains.[2][3] It is a combination of linopristin and flopristin.[4]
Clinical trials
Positive results have been reported from a phase II trial comparing it with amoxicillin.[2] Another phase II trial began in 2010 comparing it with linezolid for treatment of acute bacterial skin and skin structure infections (ABSSSI).[5] No development activity has been reported since 2015.[6]
References
- ↑ Politano AD, Sawyer RG (February 2010). "NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA". Current Opinion in Investigational Drugs. London, England. 11 (2): 225–36. PMC 3033781. PMID 20112172.
- 1 2 Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia, drugs.com
- ↑ Pankuch GA, Hoellman D, Bryskier A, Lowther J, Appelbaum PC (November 2006). "Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae". Antimicrobial Agents and Chemotherapy. 50 (11): 3914–6. doi:10.1128/AAC.00587-06. PMC 1635171. PMID 17065630.
- ↑ NXL103 at Novexel.com
- ↑ Clinical trial number NCT00949130 for "Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)" at ClinicalTrials.gov
- ↑ "Linopristin/flopristin". Adis Insight.